Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-9-23
|
| pubmed:abstractText |
To design a safe and effective synthetic peptide vaccine against rubella virus (RV) infection, it is necessary to identify immunodominant T-cell epitopes of RV structural proteins. To define such epitopes, 49 overlapping synthetic peptides (17-34 residues in length) corresponding to more than 95% of the amino acid sequence of RV virion proteins E1 (23 peptides) and C (11 peptides) and all of E2 (15 peptides) were synthesized and tested for their capacities to induce proliferative responses of rubella-specific T-cell lines and T-cell clones derived from 4 study groups (5 women infected with RV in pregnancy, 5 patients with congenital rubella syndrome, 5 seropositive healthy donors, and 5 RV vaccine recipients). The most frequently recognized epitopes were E1-21 (residues 358-377) with 11/20 responders, E2-4 (residues 54-74) with 6/20 responders, and C11 (residues 255-280) with 11/20 responders, respectively. E1-10 (residues 174-193), E1-16 (residues 272-291) and E1-18 (residues 307-326) were responded to strongly by corresponding T-cell clones, and were recognized by 4 or 5 T-cell lines. T-cell lines derived from three congenital rubella syndrome patients did not respond to any of the synthetic peptides. The results showed that more T-cell epitopes were present in E1 (19/23) and C (10/11) than in E2 (8/15). The identification of T cell sites recognized frequently by RV-infected or -immunized populations could provide the basis for selecting candidate T-cell epitopes for the development of an effective synthetic vaccine against rubella.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/E1 envelope protein, Rubella virus,
http://linkedlifedata.com/resource/pubmed/chemical/E2 envelope protein, Rubella virus,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Rubella Vaccine,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Structural Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0146-6615
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
175-83
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7689090-Adult,
pubmed-meshheading:7689090-Antigens, Viral,
pubmed-meshheading:7689090-Cell Line,
pubmed-meshheading:7689090-Child,
pubmed-meshheading:7689090-Epitopes,
pubmed-meshheading:7689090-Female,
pubmed-meshheading:7689090-Humans,
pubmed-meshheading:7689090-Lymphocyte Activation,
pubmed-meshheading:7689090-Peptide Fragments,
pubmed-meshheading:7689090-Peptide Mapping,
pubmed-meshheading:7689090-Pregnancy,
pubmed-meshheading:7689090-Rubella,
pubmed-meshheading:7689090-Rubella Syndrome, Congenital,
pubmed-meshheading:7689090-Rubella Vaccine,
pubmed-meshheading:7689090-Rubella virus,
pubmed-meshheading:7689090-T-Lymphocytes,
pubmed-meshheading:7689090-Vaccines, Synthetic,
pubmed-meshheading:7689090-Viral Envelope Proteins,
pubmed-meshheading:7689090-Viral Structural Proteins
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Mapping T-cell epitopes of rubella virus structural proteins E1, E2, and C recognized by T-cell lines and clones derived from infected and immunized populations.
|
| pubmed:affiliation |
Department of Pathology, University of British Columbia, Canada.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|